KR20240110039A - SARS-CoV-2 감염을 치료하는 방법 - Google Patents

SARS-CoV-2 감염을 치료하는 방법 Download PDF

Info

Publication number
KR20240110039A
KR20240110039A KR1020247020169A KR20247020169A KR20240110039A KR 20240110039 A KR20240110039 A KR 20240110039A KR 1020247020169 A KR1020247020169 A KR 1020247020169A KR 20247020169 A KR20247020169 A KR 20247020169A KR 20240110039 A KR20240110039 A KR 20240110039A
Authority
KR
South Korea
Prior art keywords
cov
sars
infection
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247020169A
Other languages
English (en)
Korean (ko)
Inventor
미셸 밀러
개리 딘닌 이와트
Original Assignee
바이오트론 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021903789A external-priority patent/AU2021903789A0/en
Application filed by 바이오트론 리미티드 filed Critical 바이오트론 리미티드
Publication of KR20240110039A publication Critical patent/KR20240110039A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247020169A 2021-11-24 2022-11-24 SARS-CoV-2 감염을 치료하는 방법 Pending KR20240110039A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021903789A AU2021903789A0 (en) 2021-11-24 Methods of treating sars-cov-2 infection
AU2021903789 2021-11-24
PCT/AU2022/051405 WO2023092180A1 (en) 2021-11-24 2022-11-24 Methods of treating sars-cov-2 infection

Publications (1)

Publication Number Publication Date
KR20240110039A true KR20240110039A (ko) 2024-07-12

Family

ID=86538440

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247020169A Pending KR20240110039A (ko) 2021-11-24 2022-11-24 SARS-CoV-2 감염을 치료하는 방법

Country Status (8)

Country Link
US (1) US20250009713A1 (https=)
EP (1) EP4436576A4 (https=)
JP (1) JP2024543259A (https=)
KR (1) KR20240110039A (https=)
CN (1) CN118574614A (https=)
AU (1) AU2022399231A1 (https=)
CA (1) CA3238183A1 (https=)
WO (1) WO2023092180A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260100B (zh) * 2022-08-08 2023-12-12 赛诺瑞生物医药技术(无锡)有限公司 一种用于制备冠状病毒治疗药物的取代酰基胍类化合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596107A (en) * 2005-06-24 2013-09-27 Biotron Ltd Antiviral compounds and methods
ES2563477T3 (es) * 2007-08-03 2016-03-15 Biotron Limited Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina
SG11201907034PA (en) * 2017-02-08 2019-08-27 Biotron Ltd Methods of treating influenza
US20220409587A1 (en) * 2019-11-26 2022-12-29 Biotron Limited Methods of treating hiv-1 infection
US11660307B2 (en) * 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
WO2021207049A1 (en) * 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs

Also Published As

Publication number Publication date
JP2024543259A (ja) 2024-11-20
CN118574614A (zh) 2024-08-30
WO2023092180A1 (en) 2023-06-01
CA3238183A1 (en) 2023-06-01
EP4436576A4 (en) 2025-09-17
EP4436576A1 (en) 2024-10-02
US20250009713A1 (en) 2025-01-09
AU2022399231A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
KR102607599B1 (ko) 인플루엔자의 치료 방법
US12167994B2 (en) Vidofludimus for use in the treatment or prevention of viral diseases
CN111467363A (zh) 索非布韦在制备预防和治疗冠状病毒的药物中的应用
CN111467338A (zh) 焦谷氨酸在制备预防和治疗抗新冠肺炎新型冠状病毒的药物中的应用
KR20240110039A (ko) SARS-CoV-2 감염을 치료하는 방법
EP3934653B1 (en) Azelastine as antiviral treatment
WO2022088037A1 (zh) Sirtinol在制备预防和治疗冠状病毒的药物中的应用
WO2022088047A1 (zh) Itf2357在制备预防和治疗冠状病毒的药物中的应用
JP2009522257A (ja) ウイルス感染症治療用薬剤
KR20100005063A (ko) 바이러스 감염을 치료하기 위한 스타틴 및 카페인을 포함하는 조성물
CA3052503C (en) Methods of treating influenza
TW201731515A (zh) 用於治療茲卡病毒感染之方法及組合物
WO2024027844A1 (zh) 一种药物组合物及其用途
HK40062780A (en) Vidofludimus for use in the treatment or prevention of viral diseases
CN102112461B (zh) 新型二芳基庚酮系化合物及其应用
CN120392755A (zh) 氨来占诺在制备治疗或预防呼吸道合胞病毒感染的药物的应用
CN114432283A (zh) Sirtinol在制备预防和治疗冠状病毒的药物中的应用
WO2022088038A1 (zh) Cay10603在制备预防和治疗冠状病毒的药物中的应用
CN114432305A (zh) Cay10603在制备预防和治疗冠状病毒的药物中的应用
CN114432303A (zh) 帕比司他在制备预防和治疗冠状病毒的药物中的应用
HK40017310B (en) Methods of treating influenza
HK40017310A (en) Methods of treating influenza

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000